Quince Therapeutics outlines conditional executive overhaul

Quince Therapeutics announced that Chief Executive Officer, Chief Medical Officer and director Dirk Thye and Chief Operating, Business and Compliance Officer Brendan Hannah have tendered conditional resignations.

Rhea-AI Filing Summary

Quince Therapeutics announced that Chief Executive Officer, Chief Medical Officer and director Dirk Thye and Chief Operating, Business and Compliance Officer Brendan Hannah have tendered conditional resignations. Their departures would become effective two business days after the conclusion of a Special Meeting of Stockholders anticipated on September 25, 2026, contingent on stockholder approval of three proposals: the Conversion Proposal, Minimum Price Proposal and Authorized Share Proposal.

Subject to the same effective time, the board conditionally appointed Brigette Roberts as Chief Executive Officer and Principal Executive Officer, John Militello as Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, and Keith R. Fandrick as Chief Operating Officer. Thye and Hannah will remain eligible for previously disclosed retention bonuses and severance if employed through the Special Meeting date. The board approved reducing its size from five to four directors upon Thye’s resignation and intends to add an independent director.

Positive

• None.

Negative

• CEO and senior operations leader submitting conditional resignations signals significant leadership turnover, with effectiveness tied to approval of three stockholder proposals at the September 25, 2026 Special Meeting.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

Key Figures

Board size before change: five directors Board size after change: four directors Delay after Special Meeting: two business days +1 more

4 metrics

Board size before change five directors Board approved a reduction in the size of the Board from five directors to four directors

Board size after change four directors Reduction in size of the Board from five directors to four directors upon effectiveness of Thye’s resignation

Delay after Special Meeting two business days Resignations effective as of two business days following the conclusion of the Special Meeting

Age of incoming CEO 50 Brigette Roberts, M.D., age 50, conditionally appointed as Chief Executive Officer

Key Terms

Special Meeting of Stockholders, Conversion Proposal, Minimum Price Proposal, Authorized Share Proposal, +2 more

6 terms

Special Meeting of Stockholders regulatory

"two business days following the conclusion of the Company’s Special Meeting of Stockholders"

A special meeting of stockholders is an unscheduled gathering called to let shareholders vote on specific, often urgent company decisions—like mergers, major asset sales, changes to the board, or amendments to governing rules. Think of it as an emergency town hall where owners cast ballots in person or by mail/online; outcomes can materially change a company’s strategy, control or value, so investors pay close attention and may need to vote or adjust holdings accordingly.

Conversion Proposal regulatory

"approval by the Company’s stockholders of the following three proposals, including the Conversion Proposal"

Minimum Price Proposal regulatory

"approval by the Company’s stockholders of the following three proposals, including the Minimum Price Proposal"

Authorized Share Proposal regulatory

"approval by the Company’s stockholders of the following three proposals, including the Authorized Share Proposal"

Principal Executive Officer regulatory

"conditionally appointed as the Company’s Chief Executive Officer and will serve as the Company’s Principal Executive Officer"

The principal executive officer is the highest-ranking manager who leads a company’s overall strategy, operations and public communication—often acting like the captain of a ship who sets direction and makes final calls. Investors watch this person because their decisions, credibility and ability to deliver results shape company performance, risk and market confidence, and changes in that role can directly affect stock value and corporate accountability.

Item 404(a) of Regulation S-K regulatory

"None of Drs. Roberts and Fandrick and Mr. Militello is a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership changes did Quince Therapeutics (QNCX) disclose?

Quince Therapeutics disclosed that CEO/CMO and director Dirk Thye and COO/CBO/CCO Brendan Hannah have tendered conditional resignations. The board also conditionally appointed Brigette Roberts as CEO, John Militello as CFO and Keith R. Fandrick as COO.

When will the conditional resignations at Quince Therapeutics (QNCX) become effective?

The resignations would become effective two business days after the conclusion of the Special Meeting of Stockholders, anticipated on September 25, 2026, and only if stockholders approve the Conversion, Minimum Price and Authorized Share proposals.

Who has been conditionally appointed CEO of Quince Therapeutics (QNCX)?

Brigette Roberts, M.D. has been conditionally appointed Chief Executive Officer and will serve as Principal Executive Officer. She currently serves as Chief of Corporate Affairs and a board member, and previously was CEO and Chief Medical Officer of Orphai.

What stockholder proposals affect the Quince Therapeutics (QNCX) executive transitions?

The effectiveness of the executive resignations and appointments is contingent on stockholder approval of three proposals: the Conversion Proposal, the Minimum Price Proposal and the Authorized Share Proposal, which will be presented at the Special Meeting.

How will the Quince Therapeutics (QNCX) board size change?

The board approved reducing its size from five directors to four directors immediately upon the effectiveness of Dirk Thye’s resignation. The board states that it continues to evaluate candidates and intends to appoint an independent director.

Will Quince Therapeutics’ departing executives receive bonuses or severance?

If Dirk Thye and Brendan Hannah remain employed through the Special Meeting date, they remain entitled to previously disclosed retention bonuses and to any severance amounts payable under their existing severance agreements in connection with their resignations.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/31/2026 - 04:51 PM Accepted by SEC EDGAR 07/31/2026 - 04:50 PM Learn about SEC filing dates

false 0001662774 0001662774 2026-07-29 2026-07-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 29, 2026

QUINCE THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-38890		90-1024039
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

611 Gateway Boulevard, Suite 273
South San Francisco, California		94080
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (415) 910-5717

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		QNCX		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Conditional Resignations of Dirk Thye and Brendan Hannah

On July 29, 2026, each of Dirk Thye, the Chief Executive Officer and Chief Medical Officer of Quince Therapeutics, Inc. (the “Company”), and a member of the Company’s board of directors (the “Board”), and Brendan Hannah, the Company’s Chief Operating Officer, Chief Business Officer and Chief Compliance Officer, tendered conditional resignations from their positions with the Company (including, with respect to Mr. Thye, as a member of the Board), in each case effective as of two business days following the conclusion of the Company’s Special Meeting of Stockholders, which is anticipated to be held on September 25, 2026 (the “Special Meeting”), and contingent upon the approval by the Company’s stockholders of the following three proposals to be presented at the Special Meeting (the “Effective Time”):

• To approve the issuance of shares of the Company’s common stock, upon conversion of the Company’s Series C Preferred Stock and exercise of the warrants issued pursuant to the Company’s acquisition of Orphai Holdings Therapeutics, Inc., a Delaware corporation (“Orphai HoldCo”) and Orphai Therapeutics, LLC, a Delaware limited liability company and wholly owned subsidiary of Orphai HoldCo (“Orphai Subsidiary” and, together with Orphai HoldCo, “Orphai”, and the acquisition of Orphai, the “Acquisition”) and the concurrent private placement financing (the “PIPE”) and the options to purchase Orphai Subsidiary common stock that were assumed by the Company and converted into options to purchase shares of the Company’s common stock, which will represent more than 20% of the shares of common stock outstanding pursuant to Nasdaq Listing Rule 5635(a) (the “Conversion Proposal”); and

• To approve the issuance of shares of the Company’s common stock, upon conversion of the Series C Preferred Stock issued to investors in the PIPE and upon exercise of the warrants issued to investors in the PIPE pursuant to Nasdaq Listing Rule 5635(d) (the “Minimum Price Proposal”); and

• To approve an amendment to the Company’s certificate of incorporation to increase the number of authorized shares of the Company’s common stock from 250,000,000 to 275,000,000 (the “Authorized Share Proposal” and, together with the Conversion Proposal and the Minimum Price Proposal, the “Required Company Stockholder Matters”).

For a description of the Conversion Proposal, the Minimum Price Proposal and the Authorized Share Proposal, please refer to the Company’s preliminary proxy statement on Schedule 14A filed with the Securities and Exchange Commission (the “SEC”) on July 31, 2026 (the “Preliminary Proxy Statement”).

Notwithstanding their conditional resignations, and provided that each of Mr. Thye and Mr. Hannah remain employed with the Company through the date of the Special Meeting, each of Mr. Thye and Mr. Hannah remain entitled to receive the retention bonuses previously described in the Company’s Current Report on Form 8-K filed with the SEC on May 18, 2026, and any severance amounts payable in connection with their resignations under their current severance agreements with the Company.

Conditional Appointments of Brigette Roberts, John Militello and Keith Fandrick

In connection with the foregoing, on July 29, 2026, the Board approved the following conditional appointments, each to become effective at the Effective Time:

Brigette Roberts, M.D., age 50, was conditionally appointed as the Company’s Chief Executive Officer and will serve as the Company’s Principal Executive Officer upon her appointment. Dr. Roberts has served as the Company’s Chief of Corporate Affairs and member of the Company’s Board since the closing of the Acquisition. Prior to that, she served as the Chief Executive Officer and member of the Board of Directors of Orphai from May 2021 until the closing of the Acquisition, and prior to that she served as the Chief Medical Officer of Orphai from February 2021 until May 2021. Dr. Roberts holds a B.A. in Physics and Chemistry from Harvard University and an M.D. from New York University.

John Militello, CPA, age 52, was conditionally appointed as the Company’s Chief Financial Officer and will serve as the Company’s Principal Financial Officer and Principal Accounting Officer upon his appointment. Mr. Militello has served as Head of Finance of Orphai Therapeutics, LLC since July 2026. Before joining the Company, Mr. Militello served as VP of Finance, Sr. Controller, Treasurer and Principal Accounting Officer of Rocket Pharmaceuticals, Inc., a publicly traded gene therapy company, from January 2018 to July 2026. Mr. Militello was also the Interim Principal Financial Officer of Rocket Pharmaceuticals, Inc. from January 2018 to December 2020 and March 2022 to March 2024. Previously, Mr. Militello served as the Vice President of Finance and Principal Financial and Accounting Officer at Immune Pharmaceuticals Inc. from April 2015 to November 2017. Prior to that, Mr. Militello was an Assistant Controller at Travere Therapeutics, formerly Retrophin, Inc., a publicly traded biotechnology company, and a Senior Manager in the biotech practice of BDO USA, LLP serving multi-national SEC registrants. Mr. Militello is a Certified Public Accountant and earned his Bachelor of Science degree in Accounting from St. Joseph’s College.

Keith R. Fandrick, Ph.D., age 47, was conditionally appointed as the Company’s Chief Operating Officer. Dr. Fandrick has served as the Company’s Head of Technical Operations since the Acquisition. Prior to that time, Dr. Fandrick served as Chief Operating Officer of Orphai, where he led operations, chemistry, manufacturing and controls, program management, regulatory strategy, external manufacturing and intellectual property activities for clinical-stage therapeutic programs since 2017, and he previously served in various other roles at Orphai, including as Chief Development Officer and Head of CMC. Previously, Dr. Fandrick served as a member of the Scientific Advisory Board of Drug Farm, Inc., where he advised on pharmaceutical development and CMC strategy. From 2007 to 2017, Dr. Fandrick held positions of increasing responsibility at Boehringer-Ingelheim. Dr. Fandrick is an author or co-author of 78 publications and patents. He holds Ph.D. and A.M. degrees in chemistry from Harvard University, an M.B.A. from the University of North Carolina at Chapel Hill’s Kenan-Flagler Business School, a B.S. in chemistry from the University of California, San Diego, and a Regulatory Affairs Certification.

There are no family relationships between Drs. Roberts and Fandrick and Mr. Militello and any of the executive officers or directors of the Company. There are no arrangements or understandings between Drs. Roberts and Fandrick and Mr. Militello and any other person pursuant to which either was appointed as an executive officer of the Company. None of Drs. Roberts and Fandrick and Mr. Militello is a party to any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.

Reduction in Size of the Board

The Board approved a reduction in the size of the Board from five directors to four directors immediately upon effectiveness of Dr. Thye’s resignation. The Board continues to consider potential director candidates and intends to appoint an independent director to the Board.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Quince Therapeutics, Inc.
				By:		/s/ Dirk Thye
Date: July 31, 2026				Name:		Dirk Thye
				Title:		Chief Executive Officer

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA 3.1 KB
• EX-101 XBRL TAXONOMY EXTENSION LABEL LINKBASE 17.6 KB
• EX-101 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE 11.0 KB